Literature DB >> 2147701

Photopheresis for the treatment of cutaneous T cell lymphoma.

S Armus1, B Keyes, C Cahill, C Berger, D Crater, D Scarborough, A Klainer, E Bisaccia.   

Abstract

We investigated the use of extracorporeal chemotherapy (photopheresis) in eight patients with cutaneous T cell lymphoma. Initially described by Edelson et al. for the treatment of erythrodermic cutaneous T cell lymphoma, we have expanded the treatment to include patients with extensive patch/plaque disease as well as tumor-stage disease. Four of five patients with erythrodermic stage disease had either a complete or a partial clinical remission with photopheresis alone. One patient with extensive patch/plaque disease continued to have a partial clinical remission of 7 months' duration with photopheresis alone. Of the two patients with tumor-stage disease, one remained without evidence of clinical disease at 10 months with photopheresis alone, whereas the second patient had a partial clinical remission of 5 months with a combination of local radiation therapy followed by monthly photopheresis. The skin biopsy specimen obtained from the patient with tumor-stage disease in complete clinical remission did not show cutaneous T cell lymphoma. We conclude that photopheresis is an effective modality alone or in combination with adjunctive therapy for erythroderma, extensive patch/plaque disease, and some tumor-stage disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147701     DOI: 10.1016/0190-9622(90)70312-6

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma--the Düsseldorf and Munich experience.

Authors:  B Prinz; W Behrens; E Hölzle; G Plewig
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

2.  Normal oxidative activity and chemotaxis of circulating neutrophils in patients treated with photopheresis.

Authors:  N Obel; M Storgaard; B Hansen; H Zachariae
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.